Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Arizona Oncol Assoc Dba (Hem Onc Physicians&Extenders) Hope
mi
from
Tucson, AZ
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Arizona Oncol Assoc Dba (Hem Onc Physicians&Extenders) Hope
mi
from
Tucson, AZ
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Sansum Santa Barbara Medical Foundation Clinic
mi
from
Solvang, CA
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Sansum Santa Barbara Medical Foundation Clinic
mi
from
Solvang, CA
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Ocala Oncology Center
mi
from
Ocala, FL
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Ocala Oncology Center
mi
from
Ocala, FL
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Florida Cancer Affiliates
mi
from
Trinity, FL
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Florida Cancer Affiliates
mi
from
Trinity, FL
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Summit Cancer Care
mi
from
Savannah, GA
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Summit Cancer Care
mi
from
Savannah, GA
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Lewis Hall Singletary Oncology Center
mi
from
Thomasville, GA
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Lewis Hall Singletary Oncology Center
mi
from
Thomasville, GA
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Illinois Cancer Specialists
mi
from
Niles, IL
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Illinois Cancer Specialists
mi
from
Niles, IL
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Cotton-O-Neil Clinical Research Center
mi
from
Topeka, KA
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Cotton-O-Neil Clinical Research Center
mi
from
Topeka, KA
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Anne Arundel Medical Center
mi
from
Annapolis, MD
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Anne Arundel Medical Center
mi
from
Annapolis, MD
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Center for Cancer & Blood Disorders
mi
from
Bethesda, MD
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Center for Cancer & Blood Disorders
mi
from
Bethesda, MD
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Maryland Oncology Hematology PA
mi
from
Columbia, MD
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Maryland Oncology Hematology PA
mi
from
Columbia, MD
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Jackson Oncology Associates
mi
from
Jackson, MS
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Jackson Oncology Associates
mi
from
Jackson, MS
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
St. Louis Cancer Care, LLP
mi
from
Bridgeton, MO
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
St. Louis Cancer Care, LLP
mi
from
Bridgeton, MO
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Comprehensive Cancer Centers of Nevada
mi
from
Las Vegas, NV
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Comprehensive Cancer Centers of Nevada
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
New York Oncology Hematology PC
mi
from
Albany, NY
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
New York Oncology Hematology PC
mi
from
Albany, NY
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Broome Oncology, LLC
mi
from
Johnson City, NY
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Broome Oncology, LLC
mi
from
Johnson City, NY
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Hematology Oncology Associates of Rockland
mi
from
Nyack, NY
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Hematology Oncology Associates of Rockland
mi
from
Nyack, NY
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Cone Health Cancer Center
mi
from
Greensboro, NC
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Cone Health Cancer Center
mi
from
Greensboro, NC
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Cone Health Cancer Center
mi
from
Greensboro, NC
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Cone Health Cancer Center
mi
from
Greensboro, NC
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Oncology Associates of Oregon, PC
mi
from
Eugene, OR
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Oncology Associates of Oregon, PC
mi
from
Eugene, OR
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Hematology Oncology Associates
mi
from
Medford, OR
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Hematology Oncology Associates
mi
from
Medford, OR
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Charleston Hematology/Oncology Associates, Pa
mi
from
Charleston, SC
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Charleston Hematology/Oncology Associates, Pa
mi
from
Charleston, SC
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Greenville Health System
mi
from
Greenville, SC
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Greenville Health System
mi
from
Greenville, SC
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
The Jones Clinic, PC
mi
from
Germantown, TN
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
The Jones Clinic, PC
mi
from
Germantown, TN
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Tennessee Oncology, PLLC
mi
from
Nashville, TN
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Texas Oncology-Abilene
mi
from
Abilene, TX
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Texas Oncology-Abilene
mi
from
Abilene, TX
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Texas Oncology PA - Arlington North
mi
from
Arlington, TX
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Texas Oncology PA - Arlington North
mi
from
Arlington, TX
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Texas Oncology-Beaumont
mi
from
Beaumont, TX
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Texas Oncology-Beaumont
mi
from
Beaumont, TX
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Texas Oncology, P.A.
mi
from
Bedford, TX
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Texas Oncology, P.A.
mi
from
Bedford, TX
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Texas Oncology, PA
mi
from
Dallas, TX
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Texas Oncology, PA
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Texas Oncology/Methodist Charlton Cancer Ctr.
mi
from
Dallas, TX
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Texas Oncology/Methodist Charlton Cancer Ctr.
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Texas Oncology, PA
mi
from
Dallas, TX
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Texas Oncology, PA
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Texas Oncology, P.A.
mi
from
Denton, TX
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Texas Oncology, P.A.
mi
from
Denton, TX
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Texas Oncology, P.A.
mi
from
Flower Mound, TX
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Texas Oncology, P.A.
mi
from
Flower Mound, TX
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Texas Oncology P.A.
mi
from
Fort Worth, TX
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Texas Oncology P.A.
mi
from
Fort Worth, TX
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Texas Cancer Center of Mesquite
mi
from
Mesquite, TX
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Texas Cancer Center of Mesquite
mi
from
Mesquite, TX
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Texas Oncology
mi
from
Midland, TX
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Texas Oncology
mi
from
Midland, TX
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Texas Oncology
mi
from
New Braunfels, TX
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Texas Oncology
mi
from
New Braunfels, TX
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Texas Oncology
mi
from
Paris, TX
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Texas Oncology
mi
from
Paris, TX
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Texas Oncology
mi
from
Paris, TX
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Texas Oncology
mi
from
Paris, TX
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Texas Oncology-Plano East
mi
from
Plano, TX
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Texas Oncology-Plano East
mi
from
Plano, TX
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Texas Oncology Plano West Cancer Center
mi
from
Plano, TX
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Texas Oncology Plano West Cancer Center
mi
from
Plano, TX
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Texas Oncology Cancer Center - Sugar Land
mi
from
Sugar Land, TX
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Texas Oncology Cancer Center - Sugar Land
mi
from
Sugar Land, TX
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Texas Oncology-Tyler
mi
from
Tyler, TX
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Texas Oncology-Tyler
mi
from
Tyler, TX
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Texas Oncology Cancer Care And Research Center
mi
from
Waco, TX
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Texas Oncology Cancer Care And Research Center
mi
from
Waco, TX
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Texas Oncology, P.A.
mi
from
Webster, TX
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Texas Oncology, P.A.
mi
from
Webster, TX
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Texas Oncology, P.A.
mi
from
Weslaco, TX
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Texas Oncology, P.A.
mi
from
Weslaco, TX
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Texas Oncology, PA - Wichita Falls
mi
from
Wichita Falls, TX
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Texas Oncology, PA - Wichita Falls
mi
from
Wichita Falls, TX
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Oncology and Hematology Associates of Southwest Virginia Inc.
mi
from
Blacksburg, VA
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Oncology and Hematology Associates of Southwest Virginia Inc.
mi
from
Blacksburg, VA
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Virginia Cancer Specialists, PC
mi
from
Fairfax, VA
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Virginia Cancer Specialists, PC
mi
from
Fairfax, VA
Click here to add this to my saved trials